Mets, Jacob deGrom agree to five-year, $137.5 million contract extension

Getty Images
25 Comments

The Mets have a deal on a contract extension with ace Jacob deGrom. Andy Martino of SNY was the first to report the deal. The terms, per Ken Rosenthal: five years, $137.5 million with a club option for 2024. deGrom gets a full no-trade clause and has a potential opt-out after 2022.

deGrom was slated to earn $17 million this year, so the deal contains $120.5 million in new money. There will be some restructuring, however: he’ll still get $17 million this year, but $10 million of it is as as signing bonus and $7 million of it is in salary. He’ll get $23 million in 2020, $33.5 million in 2021 and 2022 and, if he doesn’t opt-out, $30.5 million in 2023 and $32.5 million as the club option in 2024. The overall average annual value of the deal — which covers this year and next year, which would’ve been arbitration, and three potential years of free agency, is $27.5 million

Overall, the contract is very similar to the one Chris Sale just signed, even though he is a year further from free agency. deGrom will earn $107 million between now and his opt-out date. Sale will earn $105 million. Of course, if the doesn’t opt-out the deal runs through 2023, with that club option for 2024.

deGrom, the 2018 Cy Young Award winner has made no secret of his desire for a contract extension. He, likewise, has said he would not discuss the matter with the Mets after the start of the season on Thursday. This, then, is getting the job done, just under the wire.

deGrom is coming off of a season in which he posted a 1.70 ERA with 269 strikeouts and 46 walks across 217 innings. It’s the lowest ERA by a qualified starter since Zack Greinke‘s 1.66 in 2015. Prior to Greinke, no pitcher had posted an ERA of 1.70 or lower since Greg Maddux in 1994-95 (1.56, 1.63).

deGrom will turn 31 years old in June. He’ll be 35 when the deal ends or, if the option is picked up, 36.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.